Rapamycin Holdings
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
16601 Blanco Rd Ste 120, San Antonio, Te...Phone Number
(210) 876-1357Website
www.rapamycinholdings.comRevenue
$7.2 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Rapamycin Holdings
Emtora Biosciences is focused on commercializing eRapa, a novel formulation of rapamycin designed to suppress the onset and recurrence of cancer. Their pipeline targets early-stage cancers and precancerous conditions, including non-muscle invasive bladder cancer and low-grade prostate cancer. Additionally, eRapa aims to delay aging-related diseases and preserve quality of life for patients suffering from rare genetic diseases like Familial Adenomatous Polyposis (FAP). The company’s innovations are intended for clients seeking advanced cancer prevention and treatment solutions.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rapamycin Holdings your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Rapamycin Holdings is spiking on competitors!
Rapamycin Holdings, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Rapamycin Holdings had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Rapamycin Holdings has new funding data
Earning: See what the market has to say on Rapamycin Holdings recently announced quarterly report
Check if Rapamycin Holdings has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Rapamycin Holdings
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Rapamycin Holdings launches new products
Recommended Actions
Reach out to Masked Content who joined Rapamycin Holdings as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Rapamycin Holdings is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Rapamycin Holdings is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Rapamycin Holdings.
Rapamycin Holdings financials insights
Gather financial insights about Rapamycin Holdings, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$1.4M
2015
Series A
$2.5M
Rapamycin Holdings News & Media
Rapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapaTM Compound Targeting Early Stage Prostate Cancer
SAN ANTONIO--(BUSINESS WIRE)--#Cancer--Rapamycin Holdings, Inc. Opens First Human Clinical Trial of its eRapa Compound Targeting Early Stage Prostate Cancer.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rapamycin Holdings
Sign Up For FreeTo access detailed company insights
Emtora Biosciences is focused on commercializing eRapa, a novel formulation of rapamycin designed to suppress the onset and recurrence of cancer. Their pipeline targets early-stage cancers and precancerous conditions, including non-muscle invasive bladder cancer and low-grade prostate cancer. Additionally, eRapa aims to delay aging-related diseases... Read More
